Form 4: OPKO Health CEO Boosts Stake with $213K Share Purchase

OPKO Health's CEO and Chairman, Dr. Phillip Frost, acquired 150,000 shares of common stock for approximately $213,435 on October 31, 2025.

Summary

• Dr. Phillip Frost, CEO and Chairman of OPKO Health, Inc., and a 10% owner, purchased 150,000 shares of OPK common stock.
• The transaction occurred on October 31, 2025, at a weighted average price of $1.4229 per share.
• The total value of the acquisition was approximately $213,435.
• Following this transaction, Dr. Frost's indirect beneficial ownership through Frost Gamma Investments Trust is 214,386,448 shares.
• Additionally, Dr. Frost's indirect beneficial ownership through Frost Nevada Investments Trust is 30,127,177 shares.
• The shares purchased were part of multiple transactions at prices ranging from $1.415 to $1.4299, inclusive.

Sentiment

Score: 8

Explanation: The purchase of shares by the CEO and Chairman indicates strong insider confidence in the company's future, which is generally a positive signal for investors.

Positives

• Insider buying by the CEO and Chairman, Dr. Phillip Frost, indicates confidence in the company's future prospects.
• The acquisition of 150,000 shares represents a significant personal investment by a key executive, aligning management's interests with shareholders.

Future Outlook

The filing does not contain forward-looking statements or guidance, as it is a report on insider transactions.

Management Comments

• The reporting person undertakes to provide to OPKO Health, Inc., any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.
• The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

Insider buying, especially by a CEO and Chairman, is generally viewed positively by the market as it signals management's belief in the company's intrinsic value and future growth prospects, potentially differentiating it from peers where insider selling might occur.

Comparison to Industry Standards

• This Form 4 filing is a standard regulatory disclosure for insider transactions.
• The act of a CEO increasing their stake is generally seen as a positive signal, aligning management's interests with shareholders.
• While specific comparable companies or projects are not mentioned in the filing, significant insider purchases often precede periods of positive performance or strategic developments, contrasting with companies experiencing insider selling or no significant insider activity.

Stakeholder Impact

• Shareholders: Potentially positive, as insider buying can boost investor confidence and signal alignment of interests.
• Management/Employees: Reinforces leadership's commitment to the company's success.

Key Dates

Recommendation

The insider purchase by CEO and Chairman Dr. Phillip Frost is a strong signal of confidence in OPKO Health's future. This aligns management's interests with shareholders and can be a positive indicator. However, a 'hold' recommendation is appropriate as this filing alone does not provide sufficient financial or operational details to warrant a 'buy' or 'strong buy' without further analysis of the company's fundamentals and market conditions. It suggests existing investors should maintain their positions, and potential investors should view this as a favorable data point for further due diligence.

Keywords

OPKO Health, OPK, Phillip Frost, Insider Buying, Form 4, Stock Purchase, CEO, Chairman, 10% Owner, Beneficial Ownership